Antibodies

11 Sep 2007 Merck: Erbitux Phase III Study - FLEX Increases Overall Survival in First-line Treatment of Non-Small Cell Lung Cancer
11 Sep 2007 Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
08 Sep 2007 Ablynx and Boehringer Ingelheim announce major global strategic alliance to discover, develop and commercialise novel nanobody(R) therapeutics
08 Sep 2007 ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
08 Sep 2007 Genmab announces encouraging preclinical data for Ofatumumab
06 Sep 2007 Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
06 Sep 2007 Dyax Corp. and Bayer Schering Pharma AG Enter Into a Collaboration Agreement for Discovery of Therapeutic Antibodies
06 Sep 2007 Access and Somanta Announce New Data on Angiolix(R) Humanized Monoclonal Antibody
05 Sep 2007 YM BioSciences Announces positive preliminary results from Phase I/II lung cancer trial of nimotuzumab combined with radiation
05 Sep 2007 Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
04 Sep 2007 Merck Applies to Extend Use of Erbitux(R) for 1st-Line Colorectal Cancer
31 Aug 2007 YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
30 Aug 2007 Merck Serono to Reconsider Development of Matuzumab in Metastatic Colorectal Cancer Patients
30 Aug 2007 Phase II Study of IMC-A12 for Advanced Prostate Cancer Commences Patient Enrollment
29 Aug 2007 Baxter and the Alzheimer's Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients with Alzheimer's Disease
29 Aug 2007 XOMA Licenses Antibody Technology to Pfizer
25 Aug 2007 Phase II study of IMC-1121B for advanced renal cell cancer opens for patient enrollment
25 Aug 2007 Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
25 Aug 2007 Genentech announces resubmission of supplemental Biologics License Application for Avastin in combination with Paclitaxel for first-line metastatic breast cancer
24 Aug 2007 Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated
23 Aug 2007 MedImmune's motavizumab reduced RSV hospitalizations by 83 percent among high-risk native American, full-term infants in placebo-controlled Phase 3 study
22 Aug 2007 YM BioSciences', European partner, Oncoscience AG, announces initiation of advanced nimotuzumab trials in adult glioma and pancreatic cancer
22 Aug 2007 Protox acquires research program from Medicenna
21 Aug 2007 Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
21 Aug 2007 PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top